10-Q: Envoy Medical Reports Q2 2026 Results, Clinical Trial Progress

Envoy Medical, Inc. filed its Q2 2026 Form 10-Q, detailing continued net losses and progress in its Acclaim CI clinical trials, while facing substantial doubt regarding its going concern status.

Summary

• Envoy Medical, Inc. reported its financial results for the quarter ended June 30, 2026.
• The company experienced net losses of $5.98 million for the three months and $10.33 million for the six months ended June 30, 2026.
• As of June 30, 2026, the company had an accumulated deficit of $326.4 million.
• Cash and cash equivalents stood at $19.7 million, which is not expected to be sufficient for operations for at least one year.
• The company continues to focus on the development of its Acclaim Cochlear Implant (Acclaim CI) and has made progress in its pivotal clinical trial.
• All 56 patients in the Acclaim CI clinical trial have completed their activation visits, and the first 10 patients have reached their 12-month follow-up.
• The company submitted the first module of its Premarket Approval (PMA) application to the FDA on June 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern, with plans to alleviate this including potential proceeds from warrant exercises or other financing sources.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, substantial accumulated deficit, and the ongoing substantial doubt about the company's ability to continue as a going concern, despite progress in clinical trials.

Positives

• Progress in the Acclaim CI clinical trial, with all 56 patients completing activation visits and initial follow-up milestones being met.
• Submission of the first module of the Premarket Approval (PMA) application to the FDA on June 30, 2026.
• Increased cash balance to $19.7 million as of June 30, 2026, from $3.7 million as of December 31, 2025, largely due to the February 2026 offering.
• The company has a Breakthrough Device Designation from the FDA for the Acclaim CI.
• The Esteem FI-AMEI is the only fully implanted hearing device to have received FDA approval.

Negatives

• Continued net losses of $5.98 million for Q2 2026 and $10.33 million for the first six months of 2026.
• A substantial accumulated deficit of $326.4 million as of June 30, 2026.
• The company's current cash balance of $19.7 million is insufficient to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern.
• Net revenues decreased by 34.6% to $51,000 for the three months ended June 30, 2026, compared to the prior year period.
• Cost of goods sold increased by 18.8% for the three months ended June 30, 2026, outpacing revenue growth.
• The company anticipates continued net losses and increasing expenses for the foreseeable future.
• Material weaknesses in internal control over financial reporting were identified, including lack of a formal risk assessment and inadequate accounting policies and procedures.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to ongoing operating losses and insufficient cash reserves.
• The Acclaim CI has not yet received FDA approval, and there is no guarantee it will be approved.
• The company may be unable to raise sufficient financing when needed, which could lead to delays or termination of planned activities.
• The medical device industry is highly competitive, and the company may fail to introduce new products or compete effectively.
• Changes in federal or state reimbursement policies could adversely affect sales.
• The company is subject to legal proceedings, including a complaint from Atlas Merchant Capital SPAC Fund I LP, which could result in significant damages.
• The company's stock price is subject to volatility, and the market price of its Class A Common Stock may fluctuate significantly.
• The company's ability to maintain the listing of its securities on The Nasdaq Stock Market LLC is a risk factor.

Future Outlook

The company expects to continue incurring net losses and increasing expenses for the foreseeable future due to ongoing clinical trials for the Acclaim CI and preparation for potential commercialization. The company anticipates obtaining the FDA's decision on its PMA application for the Acclaim CI within the second half of 2027 or the first half of 2028. If regulatory approval is obtained, significant commercialization expenses are expected. The company plans to finance its operations through equity offerings, debt financings, or other capital sources.

Management Comments

• The company believes leveraging the ears natural anatomy, rather than an external or sub-dermal artificial microphone, is the ideal way for people to hear.
• The Acclaim CI gives us the opportunity to disrupt the existing cochlear implant market.
• The FDA approval process is uncertain and there can be no guarantees of whether the Acclaim CI will ever successfully receive FDA approval.
• We expect that our R&D expenses will continue to increase for the foreseeable future as we continue the clinical trials for the Acclaim CI product and prepare the product for possible commercialization, should it gain regulatory approval(s).

Industry Context

StockSavvy.ai notes that Envoy Medical operates in the highly competitive hearing health sector, aiming to disrupt the cochlear implant market with its fully implanted Acclaim CI. The company's focus on leveraging natural ear anatomy contrasts with traditional external or behind-the-ear devices. The success of the Acclaim CI hinges on FDA approval and navigating established reimbursement pathways, a challenge faced by its previous product, the Esteem FI-AMEI.

Comparison to Industry Standards

• The Acclaim CI is positioned as a first-of-its-kind fully implantable cochlear implant, aiming to differentiate from existing cochlear implant technologies.
• The company's previous product, the Esteem FI-AMEI, received FDA approval in 2010 and remains the only fully implanted active middle ear hearing device with FDA approval, though it did not achieve commercial traction due to reimbursement issues.
• The company is utilizing the FDA's modular PMA pathway, allowing for submission of completed sections for review, which is a strategic approach to regulatory engagement.
• The company's clinical trial for the Acclaim CI involves 56 patients, a standard cohort size for pivotal trials in the medical device industry.

Corporate Governance

Legal Proceedings

• Atlas Merchant Capital SPAC Fund I LP v. Envoy Medical, Inc., et al.: A lawsuit alleging that Atlas was not allowed to redeem its shares and that defendants acted to prevent redemption. Damages asserted are approximately $9.4 million. The court partially granted a motion to dismiss, narrowing the issues.
• Interest Related to an Uncertain Tax Position: The IRS has asserted that interest is due on a tax payment refund. The company believes any interest computation should be limited to the period it had use of the funds. Potential payment up to approximately $150,000.

Related Party Transactions

• Lease of headquarters office space from a company owned by a stockholder.
• Term loans were received from GAT Funding, LLC (controlled by a former board member and stockholder) and were extinguished on August 25, 2025.
• Shared services arrangement with a company indirectly owned by a stockholder for certain support services.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, volatility in stock price, and the ongoing risk of the company's ability to continue as a going concern.
• Creditors: The company's going concern status may impact its ability to meet its financial obligations.
• Employees: Continued employment is dependent on the company's ability to secure future financing and achieve regulatory approval.
• Suppliers: Potential impact on payment terms or order volumes if the company faces financial distress.

Next Steps

• Continue clinical trials for the Acclaim CI product.
• Prepare and submit the Premarket Approval (PMA) application to the FDA.
• Seek regulatory approvals in jurisdictions outside the United States.
• Establish a sales, marketing, and distribution infrastructure for potential commercialization.
• Continue to protect and expand the company's intellectual property portfolio.
• Hire and retain additional skilled personnel.
• Implement remediation measures for material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company shows progress in its clinical trials and regulatory submissions for its Acclaim CI, which is a positive development. However, the significant net losses, substantial accumulated deficit, and the ongoing substantial doubt about its ability to continue as a going concern present considerable risks. The current cash position is insufficient for the next 12 months without additional financing. Therefore, a 'hold' recommendation is appropriate, balancing the potential upside from regulatory approval against the significant financial and operational risks.

Keywords

hearing health, fully implanted hearing devices, Acclaim CI, Esteem FI-AMEI, cochlear implant, FDA approval, clinical trial, Premarket Approval